NFE2L2 and metabolic dysfunction-associated steatotic liver disease: These results indicate that the identified inducers of HMOX1 have the potential to ameliorate steatosis in vitro, further supporting the potential use of NRF2 inducers as therapeutic agents for NAFLD.